Clinical trials
Metastatic Breast Cancer clinical trials
Below are recruiting metastatic breast cancer clinical trials, each written for real people, not researchers. We’re tracking 1,312 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03829553RecruitingPhase 3
Radiation to breast lymph nodes versus standard breast cancer care
This Phase 3 trial tests whether a shorter, more focused radiation treatment to the regional lymph nodes works as well as the current standard approach for certain breast cancers. It may help patients by potentially improving treatment efficiency while keeping cancer control effective.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT04925856Recruiting
Monitoring the immune system during breast cancer drug treatment
This study looks at how your immune system changes while you receive standard breast cancer treatments. The researchers measure immune-related signals during your treatment to better understand what may be happening in triple-negative or certain hormone-receptor breast cancers.
BesançonAges 18–85 - NCT05891093RecruitingPhase 3
Fluzoparib plus hormone therapy after surgery for breast cancer
This Phase 3 trial tests whether fluzoparib added to standard hormone (endocrine) therapy after early breast cancer surgery can improve outcomes and safety. It may help patients whose tumors are ER-positive, HER2-negative, and a specific SNF3 subtype.
Beijing, Beijing MunicipalityAges 18–70 - NCT07829848Recruiting
Skip extra radiation for breast cancer patients who respond well to treatment
This trial tests whether women and men with advanced, non-metastatic breast cancer can safely skip an extra radiation boost to the lymph nodes if their tumors respond well to pre-surgery chemotherapy or targeted therapy. The goal is to reduce side effects while keeping cancer control.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06548919Recruiting
Treatment patterns for ESR1-mutated advanced breast cancer
This study looks at how Chinese patients with a specific gene change (ESR1 mutation) in ER-positive, HER2-negative advanced breast cancer are currently being treated. It will help doctors understand what treatments work best for people whose cancer has stopped responding to hormone therapy.
Suzhou, JiangsuAges 18 years+ - NCT07612215RecruitingPhase 1/Phase 2
Elacestrant for Advanced Triple-Positive Breast Cancer
This trial tests a new drug called elacestrant for advanced breast cancer that is triple-positive (positive for three hormone receptors: ER, PR, and HER2). The drug may help slow or shrink cancer that has progressed despite previous treatments.
New York, New YorkAges 18 years+ - NCT07600957Recruiting
Polarized Light Therapy to Ease Radiation Skin Damage
This trial tests whether a special type of light therapy can reduce skin damage and irritation that happens during radiation treatment for breast cancer. If it works, it could help patients feel more comfortable during and after their radiation therapy.
Banī SuwayfAges 35–55 - NCT06757621RecruitingPhase 3
Shorter Radiation for Intermediate-Risk Breast Cancer
This trial is testing a shorter course of radiation (called hypofractionated radiation) to the lymph nodes around the breast area after surgery for women with intermediate-risk breast cancer. The goal is to see if this approach works as well as standard radiation while possibly reducing side effects.
Beijing, Beijing MunicipalityAges 45 years+ - NCT07500012Recruiting
Ear nerve stimulation for breast cancer pain
This study tests whether gentle electrical stimulation of a nerve in your ear (called taVNS) can help reduce pain and improve symptoms for breast cancer survivors. You would need to have finished your main treatments, have ongoing pain, and be willing to provide stool samples and undergo brain scans.
Tallahassee, FloridaAges 18–79 - NCT06171360Recruiting
Gut bacteria and CDK4/6 inhibitor treatment in breast cancer
This study looks at how gut bacteria affect response to a type of targeted therapy (CDK4/6 inhibitors) combined with hormone therapy in breast cancer that is hormone receptor-positive and HER2-negative. It may help find out why some people respond better to treatment and could lead to better personalized care.
BrusselsAges 18–100 - NCT07396324RecruitingPhase 2
A new drug before surgery for HR+ HER2- breast cancer
This trial tests whether the drug QL1706, given before surgery, can help treat hormone receptor positive and HER2-negative breast cancer. It is for people who have not yet had cancer spread to other parts of the body.
ShanghaiAges 18 years+ - NCT07397585Recruiting
SBRT for Limited Metastatic Breast Cancer: A Database Study
This study looks back at medical records of people with breast cancer that has spread to only a few spots (oligometastases) who received a special type of radiation called SBRT. It aims to learn how well this treatment works and to help doctors better understand who benefits most.
Benevento, BeneventoAges 18 years+ - NCT07235176RecruitingPhase 1/Phase 2
QLS1304 plus hormone therapy for ER+ breast cancer
This trial tests a new drug called QLS1304 combined with hormone therapy for people with ER-positive, HER2-negative breast cancer that has spread or come back and no longer responds to hormone therapy alone. The goal is to see if this combination can help shrink tumors or slow the disease.
ShanghaiAges 18 years+ - NCT05406635Recruiting
Imaging vs blood tests to guide heart-safe HER2 treatment
This trial compares whether special heart imaging or blood tests better helps monitor heart safety while you receive HER2-targeted therapy (like trastuzumab, with or without pertuzumab) plus chemotherapy. It may help doctors catch early heart stress and choose the safest treatment plan for you.
AalborgAges 18–90 - NCT07047365RecruitingPhase 3
New drug for HER2-positive advanced breast cancer
This trial tests a new medicine called TQB2930 for people with advanced breast cancer that is HER2-positive. It is for those who have already had at least two prior anti-HER2 treatments and are willing to also receive chemotherapy chosen by their doctor.
Bengbu, AnhuiAges 18–75 - NCT06976944RecruitingPhase 2
Pembrolizumab, Paclitaxel, and Bevacizumab for Triple-Negative Breast Cancer
This trial tests a combination of the immunotherapy drug pembrolizumab, the chemotherapy paclitaxel, and possibly the targeted drug bevacizumab for people with triple-negative breast cancer that has returned after treatment. It aims to see if adding bevacizumab improves outcomes for patients whose tumors are PD-L1 positive.
Nagoya, Aichi-kenAges 18 years+ - NCT06927102Recruiting
Bringing back breast cancer patients lost to follow-up
This study looks at people with breast cancer who stopped coming to follow-up appointments. It aims to understand why they dropped out and help them re-engage with care.
Hyderabad, TelanganaAges 18 years+ - NCT06929910Recruiting
K4Care test study for metastatic cancer patients
This study tests how well the K4Care blood test can monitor treatment in people with advanced solid tumors like lung, colorectal, breast, or stomach cancer that has spread. Researchers want to see if tracking tumor DNA in the blood helps guide therapy.
Ho Chi Minh City, Hồ Chí MinhAges Any age - NCT05862064RecruitingPhase 3
Adding an immune drug and anti-blood-vessel treatment to chemo
This study tests whether adding an immune therapy (a PD-1 antibody) plus a blood-vessel–blocking treatment to standard chemo improves outcomes for people with surgically treated triple-negative breast cancer. Everyone gets chemotherapy, but some will also get the added drugs to try to reduce cancer coming back.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06059469RecruitingPhase 2
PSMA scan for advanced triple-negative breast cancer
This trial uses a special scan (PSMA-PET/CT) to see if your breast cancer makes a protein called PSMA. The results might help guide your future treatment.
BrusselsAges 18 years+ - NCT06586047RecruitingEarly Phase 1
PSMA PET scan for triple-negative breast cancer
This trial uses a special PET scan to see if PSMA, a protein on some cancer cells, can help detect triple-negative breast cancer that has spread to other parts of the body.
Iowa City, IowaAges 18–90 - NCT06349512Recruiting
PET scan to predict treatment response in triple-negative breast cancer
This trial uses a special PET scan (68Ga-FAPI-46) to see if it can predict how well chemotherapy plus immunotherapy (pembrolizumab) works in people with triple-negative breast cancer before surgery. It aims to help doctors understand if the treatment is effective earlier.
AntonyAges 18 years+ - NCT06225505Recruiting
Early detection of triple-negative breast cancer return
This trial uses blood tests to look for signs of cancer returning early in women who had triple-negative breast cancer. If caught early, doctors can start treatment sooner.
AvignonAges 18 years+ - NCT05872347RecruitingPhase 2
Brain metastasis breast cancer trial with hormone therapy plus SPH4336
This trial tests whether SPH4336, added to standard hormone (endocrine) therapy, can improve outcomes for people with breast cancer that has spread to the brain. It also looks closely at safety and side effects.
Hefei, AnhuiAges 18–75
Hear when a new Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic breast cancer?
- Yes. Clin2 currently lists 1,312 recruiting metastatic breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Breast Cancer (Triple Negative Breast Cancer (TNBC))
- Locally Advanced or Metastatic Breast Cancer
- Metastatic Triple-negative Breast Cancer
- HER2-positive Metastatic Breast Cancer
- Advanced/Metastatic Breast Cancer
- Non-metastatic Breast Cancer
- Advanced or Metastatic Breast Cancer
Beyond the search
We also like to point to nonprofits doing real good in this area. We aren’t affiliated with them — we just admire the work.
- Stand Up To CancerPeople facing cancer across many types, through the research that leads to better treatments.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.